Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.
暂无分享，去创建一个
J. Sancho | U. Jaeger | Xiwen Ma | G. Follows | J. Kuruvilla | J. Zijlstra | N. Kalakonda | S. Choquet | A. Goy | B. Hill | F. Cavallo | J. Vermaat | F. Offner | K. Warzocha | C. Thieblemont | P. Caimi | R. Casasnovas | S. Shacham | T. Vassilakopoulos | S. Bakhshi | R. Gurion | M. Maerevoet | N. Hamad | K. Chamoun | M. Kauffman | M. Egyed | E. Neste | F. de la Cruz | P. Samal | Michaela Schuster | K. Corona | M. Canales | J. Shah | M. Ku